Download to read offline
Uploaded byMarilyn Mann
Alirocumab effect on new-onset or worsening diabetes, blood glucose, and HbA1c.
In 9 randomized clinical trials of alirocumab including 2482 patients, 3.4% of patients on alirocumab reported treatment-emergent diabetes or worsening of preexisting diabetes compared to 3.1% of patients on placebo. Laboratory tests found that at 52 weeks, patients on alirocumab on average saw a 0.16 mmol/L increase in fasting glucose levels and a 0.10% increase in hemoglobin A1c levels compared to placebo.
Alirocumab effect on new-onset or worsening diabetes, blood glucose, and HbA1c.
- 1. Data abstractedfrom ACC15AbstractA1363, PooledSafetyandAdverseEventsinNine Randomized, Placebo-Controlled,Phase 2andPhase 3 Clinical Trialsof Alirocumab. J Am Coll Cardiol. 2015; 65(10_S). doi: 10.1016/S0735-1097(15)61363-8. Alirocumab Placebo N=2482 N=1277 Adverse events,%(n) Anytreatment-emergent diabetesorworseningof preexistingdiabetes 3.4 (83) 3.1 (40) Otherclinical laboratorydata. Week52 change frombaseline. N=2318 N=1174 Fastingglucose,mmol/L,mean (SD) 0.16 (1.52) 0.13 (1.64) HemoglobinA1c%,mean(SD) 0.10 (0.66) 0.07 (0.54)